FibroBiologics, Inc. (FBLG)

NCM – Real vaqt narxi. Valyuta: USD

1.11

+0.08 (7.77%)

Yopilishda: Aug 12, 2026, 4:00 PM EDT

1.07

-0.04 (-3.60%)

Bozordan keyin: Aug 12, 2026, 4:23 PM EDT

11.08.2026

FibroBiologics Granted U.S. Patent Covering the Use of Fibroblasts to Enhance Survival and Function of Transplanted Insulin-Producing Islets

Patent has potential for applications beyond diabetes, including other cell and tissue transplantation procedures HOUSTON, Aug. 11, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,691,147, entitled "Methods and Compositions for Treatment of Type 1 Diabetes Using Fibroblasts in Facilitation of Islet Engraftment.

05.08.2026

FibroBiologics Granted European Patent Covering Gene Therapy for the Regeneration of Cartilage

Granted claims cover Sox9-based conversion of fibroblasts into cartilage-producing cells, supporting the Company's orthopedics and degenerative disc pathways HOUSTON, Aug. 5, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that the European Patent Office (EPO) has granted the Company's patent entitled "Gene Therapy for the Regeneration of Chondrocytes or Cartilage Type Cells." The granted patent, European Patent No.

31.07.2026

FibroBiologics Reports Second Quarter 2026 Financial Results; Progresses Clinical Trial Evaluating Lead Wound Care Candidate

- First patients dosed in phase 1/2 clinical trial evaluating CYWC628 in diabetic foot ulcers - On track for interim results reporting in 2H 2026 HOUSTON, July 31, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update. Recent Highlights: Clinical Updates: Initiation of patient dosing in the Company's Phase 1/2 clinical trial evaluating CYWC628 for the treatment of diabetic foot ulcers (DFUs).

Videolar

No Data

There is no data to display

Press-relizlar

11.08.2026

FibroBiologics Granted U.S. Patent Covering the Use of Fibroblasts to Enhance Survival and Function of Transplanted Insulin-Producing Islets

05.08.2026

FibroBiologics Granted European Patent Covering Gene Therapy for the Regeneration of Cartilage

31.07.2026

FibroBiologics, Inc. (FBLG)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

FibroBiologics, Inc. (FBLG)

FibroBiologics Granted U.S. Patent Covering the Use of Fibroblasts to Enhance Survival and Function of Transplanted Insulin-Producing Islets

FibroBiologics Granted European Patent Covering Gene Therapy for the Regeneration of Cartilage

FibroBiologics Reports Second Quarter 2026 Financial Results; Progresses Clinical Trial Evaluating Lead Wound Care Candidate

Videolar

No Data

Press-relizlar

FibroBiologics Granted U.S. Patent Covering the Use of Fibroblasts to Enhance Survival and Function of Transplanted Insulin-Producing Islets

FibroBiologics Granted European Patent Covering Gene Therapy for the Regeneration of Cartilage

FibroBiologics Reports Second Quarter 2026 Financial Results; Progresses Clinical Trial Evaluating Lead Wound Care Candidate

FibroBiologics Granted U.S. Patent Covering the Use of Fibroblasts to Enhance Survival and Function of Transplanted Insulin-Producing Islets

FibroBiologics Granted European Patent Covering Gene Therapy for the Regeneration of Cartilage

FibroBiologics Reports Second Quarter 2026 Financial Results; Progresses Clinical Trial Evaluating Lead Wound Care Candidate

Videolar

No Data

Press-relizlar

FibroBiologics Granted U.S. Patent Covering the Use of Fibroblasts to Enhance Survival and Function of Transplanted Insulin-Producing Islets

FibroBiologics Granted European Patent Covering Gene Therapy for the Regeneration of Cartilage

FibroBiologics Reports Second Quarter 2026 Financial Results; Progresses Clinical Trial Evaluating Lead Wound Care Candidate

Search stocks

FibroBiologics, Inc. (FBLG)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

FibroBiologics, Inc. (FBLG)

FibroBiologics Granted U.S. Patent Covering the Use of Fibroblasts to Enhance Survival and Function of Transplanted Insulin-Producing Islets

FibroBiologics Granted European Patent Covering Gene Therapy for the Regeneration of Cartilage

FibroBiologics Reports Second Quarter 2026 Financial Results; Progresses Clinical Trial Evaluating Lead Wound Care Candidate

Videolar

No Data

Press-relizlar

FibroBiologics Granted U.S. Patent Covering the Use of Fibroblasts to Enhance Survival and Function of Transplanted Insulin-Producing Islets

FibroBiologics Granted European Patent Covering Gene Therapy for the Regeneration of Cartilage

FibroBiologics Reports Second Quarter 2026 Financial Results; Progresses Clinical Trial Evaluating Lead Wound Care Candidate

FibroBiologics Granted U.S. Patent Covering the Use of Fibroblasts to Enhance Survival and Function of Transplanted Insulin-Producing Islets

FibroBiologics Granted European Patent Covering Gene Therapy for the Regeneration of Cartilage

FibroBiologics Reports Second Quarter 2026 Financial Results; Progresses Clinical Trial Evaluating Lead Wound Care Candidate

Videolar

No Data

Press-relizlar

FibroBiologics Granted U.S. Patent Covering the Use of Fibroblasts to Enhance Survival and Function of Transplanted Insulin-Producing Islets

FibroBiologics Granted European Patent Covering Gene Therapy for the Regeneration of Cartilage

FibroBiologics Reports Second Quarter 2026 Financial Results; Progresses Clinical Trial Evaluating Lead Wound Care Candidate